Guardian Pharmacy price target raised to $28 from $25 at Raymond James

Raymond James analyst John Ransom raised the firm’s price target on Guardian Pharmacy (GRDN) to $28 from $25 and keeps an Outperform rating on the shares. The company’s Q1 results were ahead of the firm’s model on revenue, but $600,000 below on EBITDA due to some pull-forward on Heartland integration costs and a slight miss on seasonality, the analyst tells investors in a research note. This was a solid quarter with no major surprises outside of the small seasonality change, and Raymond James continues to like Guardian for its solid organic and inorganic growth potential, clean balance sheet with dry powder for M&A, and performance of operational execution.